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Atrial ﬁbrillation (AF) is the most common sustained arrhythmia that is associated with signiﬁcant morbidity and mortality.
Current available therapies remain inadequate in symptom control and secondary prevention and are often associated with
signiﬁcant side eﬀects. The mechanisms underlying the pathogenesis of AF are poorly understood, although electrophysiological
remodeling has been described as an important initiating step. Recently, increasing evidence implicates oxidative stress and
inﬂammation in the pathogenesis of AF. We searched the literature for evidence to support the use of antioxidant vitamins C
and E in the prevention of AF. These vitamins, through their reactive-oxygen-species- (ROS-) scavenging eﬀect, have shown
a role in AF prevention in both animal and small clinical studies. The available evidence, however, is currently insuﬃcient to
support recommendations for their use in the wider patient population. Larger-scale clinical studies are required to conﬁrm these
preliminary results. Research is also required to further the understanding of the processes involved in the pathogenesis of AF and
the role of antioxidant therapies to prevent the arrhythmia.
1.Introduction
Atrial ﬁbrillation (AF) is the most frequent arrhythmia in
the general population and commonest rhythm disturbance
after cardiac surgery with a reported incidence of 20% to
50% [1, 2]. According to large epidemiological studies in
Europe and in the USA, lifetime risk of developing AF has
been estimated to be 1 in 4 for men and women over the age
of 40 [3, 4]. The prevalence of AF doubles each decade with
advancingage,from0.5%attheageof50,toalmost9%atthe
age of 80–89 years [5]. In a recent UK survey of 4843 people
aged over 65, AF was found in 4.7% [6]. Projected data from
North America suggests that AF is expected to aﬀect up to
15.9 million people by 2050 [7], and as the observed trend
in AF continues to increase, many consider it as the new
epidemic[8].AFisassociatedwithsubstantialmorbidityand
mortality as it can lead to thromboembolism and impaired
cardiac function. It is also an independent risk factor for
death, with a risk ratio of 1.5 for men and 1.9 for women
[9].
Postoperative AF (POAF) has a peak incidence on the
second and third postoperative days [10]. It is often self-
limiting as up to 80% of patients return to sinus rhythm by
day 3 following correction of electrolyte abnormalities and
treatmentwithβ-blockers,amiodaroneordigoxin.Nonethe-
less, the onset of POAF may not only signiﬁcantly prolong
hospital stay [11, 12] but may also result in haemodynamic
compromise, ventricular arrhythmias, postoperative stroke,
myocardial infarction (MI), and heart failure.
The currently available drug therapies for AF have major
limitations. They are often associated with treatment failure
and proarrhythmic complications, and their prognostic ben-
eﬁt is limited. Radiofrequency ablation has recently shown
promising results but is an invasive procedure and it is indi-
cated only in selected patients where conventional antiar-
rhythmics have failed to provide symptomatic control.2 Cardiology Research and Practice
Recently, increased eﬀort has been made in the understand-
ing of the pathogenesis of AF and the development of novel
therapies to prevent AF, some of which aim at the susceptible
structural and physiological substrate.
This paper aims to summarise the current evidence sur-
rounding the use of antioxidant vitamins for the primary
and secondary prevention of AF. Furthermore, we propose
a potential mechanism by which antioxidant vitamins may
exhibitthiseﬀect,providingusefulinsightsintotheoxidative
stress hypothesis in AF.
2. Methods
We carried out an extensive MEDLINE and EMBASE
search (1966—November 2010) for original articles, reviews,
and meta-analyses using MeSH terms: “atrial ﬁbrillation,”
“arrhythmias,” “antioxidants,” “vitamin C,” “ascorbic acid,”
“vitamin E,” “tocopherol,” and “vitamin A”. All papers se-
lected were in the English language. We also conducted a
“related articles” search for articles identiﬁed in MEDLINE.
Further relevant papers were examined from reference lists
of identiﬁed articles. Articles were ﬁltered for studies that
looked at antioxidant vitamins in the prevention of AF.
3. Pathogenesis of Atrial Fibrillation:
The Role of OxidativeStress
AF is thought to result from multiple random reentrant
wavelets that propagate within the atria, perpetuating the
atrial arrhythmia. It is a progressive disease, as once it is
present it results in electrophysiological and structural re-
modeling that sustains further AF [13, 14]. An important
step in the pathogenesis of AF is electrophysiological remod-
eling, a term that describes changes that aﬀect excitability
and electrical activity of cardiac myocytes [13–15]. The atria
in AF are characterised by a diminished action potential and
shortening of eﬀective refractory period [13]. The mech-
anism by which electrophysiological remodeling occurs is
poorly understood, though evidence increasingly supports
the role of oxidative stress as the key mediator in this process
[16–19].
Abnormalities in myocyte calcium handling have been
implicated as an important step in initiating the process of
atrial electrophysiological remodeling. It is thought that AF
initiationistheresultofcalciumoverload,whereaspersistent
or chronic AF is associated with a reduction in myocyte L-
type voltage-gated Ca2+ current [13]. The exact mechanism
by which calcium abnormalities can cause electrophysiologi-
calremodelingisunknown,thoughincreasedoxidativestress
may play a role [13, 20, 21].
Oxidative stress results from excessive reactive oxy-
gen species (ROS), which are chemically reactive, oxygen-
containing ions and small molecules. They are involved in
pathological processes such as DNA damage, apoptosis, and
c e l l u l a rh y p e r t r o p h ya sw e l la ss i g n a lp a t h w a ym o d u l a t i o n
[21]. The transient nature of free radicals and complexity
of available techniques make their measurement in humans
diﬃcult. Consequently, a number of surrogate markers are
used to assess levels of oxidative stress. Peroxynitrite is a
free radical that leads to oxidation of cellular lipids, proteins,
and DNA, which can therefore aﬀect protein and enzyme
structure and function and cell death [22]. In a study by
Mihmandcolleagues,myoﬁbrillarproteinswereinvestigated
for evidence of oxidative posttranslational protein modiﬁ-
cation [18]. The excised atrial appendages of patients with
AF had increased levels of nitrotyrosine and protein car-
bonyls,markersofperoxynitriteandhydroxylradicalprotein
interaction, respectively. In addition, there was evidence of
a direct interaction of peroxynitrite with creatinine kinase,
causing oxidative damage associated with atrial myoﬁbrillar
energetic impairment [18]. Carnes et al. used atrial burst
pacing to produce a canine model of atrial ﬁbrillation and
conﬁrmed increased levels of protein nitration (suggesting
the presence of peroxynitrite anions), increased plasma free
radicals, and decreased tissue levels of ascorbate in this
model. Furthermore, oral supplementation of ascorbate was
shown to attenuate these changes [15].
The pathophysiological link between oxidative stress and
AF is unclear. It has been postulated that derangement of
ion channel regulatory mechanisms by oxidative stress may
be responsible. Activity of the sodium channel is particularly
linked with the development of AF [23], and the slowly
inactivating sodium currents are reduced by oxidative stress
[24]. Peroxide, produced by NADPH oxidase, may increase
the amplitude of Kv1.5 channel currents, aﬀecting the action
potential repolarisation phase, and hence lead to AF initia-
tion or perpetuation [25–27]. Finally, reduced functionality
of L-type calcium channels in AF may help perpetuate the
arrhythmia; the reversal of this eﬀect by statins is thought to
be a function of their antioxidant activity [28].
4. OxidativeStress in the Pathogenesis of
PostoperativeAtrialFibrillation
Cardiac surgery is characterised by acute ischaemic and
reperfusion injury, which leads to the release of ROS, causing
oxidative stress and a systemic inﬂammatory response [29].
Although ischaemia/reperfusion plays an important role,
some other factors may also contribute. For example, extra-
corporeal circulation activates inﬂammatory cells and in-
creasesoxidativestress,thoughthisdeleteriouseﬀectappears
abrogated by oﬀ-pump cardiac surgery techniques [30–33].
Moreover, pericardial injury and inﬂammation after cardiac
surgery may directly increase atrial oxidative stress, and it
is related to atrial arrhythmias [34]. In an experimental
study using electron-spin-resonance techniques, reperfusion
was shown to generate free radicals, an eﬀect attenuated by
antioxidantscavengers[35].Inaddition,apersistentincrease
in plasma lipid peroxidation levels and cardiac release of
oxidised glutathione (a marker of oxidative stress) has been
demonstrated for 24 hours following aortic cross-clamp re-
lease after coronary artery bypass grafting (CABG) [36].
Similarly, Milei and colleagues also showed that following
CABGsurgerypatientshadincreasedcardiacreleaseofgluta-
thione and reduced myocardial levels of antioxidant markers
such as vitamin E and ubiquinol [37]. These studies suggestCardiology Research and Practice 3
the development of oxidative stress in cardiac surgery, which
may account for the high rate of POAF.
5.AntioxidantVitaminsandAtrial
FibrillationPrevention
Normally, cells protect themselves from ROS damage with
antioxidant substances including enzymes such as superox-
ide dismutases, catalases, glutathione peroxidases, and per-
oxiredoxins. Cells also contain small antioxidant molecules
including vitamin C (ascorbic acid), vitamin E (tocopherol),
uric acid, and reduced glutathione, which play a vital role in
cell protection from oxidant injury. Vitamin C and vitamin
E are essential antioxidants and, as such, deserve particular
consideration.
Both vitamin C and vitamin E act by reducing ROS [19].
Vitamin C has been shown to be a major intracellular an-
tagonist of peroxynitrite [38, 39], and it is thought that
vitamin E works synergistically with vitamin C. Once alpha-
tocopherol is oxidised into alpha-tocopheroxyl radical, it
requires an electron donor, such as vitamin C to reduce it, so
it can once again function as an antioxidant [40]. Therefore,
vitamin C through its direct radical scavenger action and
its ability to recycle vitamin E reducing potential is a very
eﬀective antioxidant. A summary of the experimental and
clinical evidence for the use of antioxidant vitamins in AF
prophylaxis is shown in Tables 1 and 2,r e s p e c t i v e l y .
6.VitaminCandAtrialFibrillation:
ExperimentalStudies
A number of studies have examined the role of antioxidant
therapies in the prevention of AF with a particular focus
on the atrial tissue surrounding the pulmonary veins (PVs),
identiﬁed as a source of spontaneous premature depolarisa-
tions that trigger and sustain AF [48, 49]. In a recent study,
Lin and colleagues investigated the electrophysiological ef-
fectsofoxidativestressonPVsandtheabilityofascorbicacid
toattenuatethesechanges[41].Hydrogenperoxide,aknown
ROS,inducedburstﬁringandincreasedspontaneousactivity
in PV tissue. These changes were suppressed by pretreatment
ofPVtissuewithascorbicacid,suggestingoxidativestresshas
direct physiological eﬀects on PVs, which are attenuated by
ascorbic acid.
In their canine model of AF, Carnes and colleagues
demonstrated a shortening of the atrial eﬀective refractory
period (ERP) with rapid atrial pacing. Treatment with ascor-
bate attenuated the pacing-induced atrial ERP shortening
following 24 to 48 hours of pacing. This is in keeping
with the established link between ERP changes and early
development of AF [15]. In their study, Shiroshita-Takeshita
et al. compared the eﬀect of vitamin C and E on atrial
remodeling to that of simvastatin [28]. Dogs were ﬁtted with
internal atrial pacing and were subjected to 1 week of atrial
tachypacing. Their results are in contrast to those of Carnes
et al. as vitamin C and E had no eﬀect on ERP and did
not prevent AF, whereas simvastatin both prevented AF and
abrogatedthe ERP-shortening eﬀect.Theprecise mechanism
by which statins prevent AF is not well known, although it is
thought to be a consequence of both anti-inﬂammatory and
antioxidant eﬀects [50, 51].
7. Prevention of Postoperative AF
Carnes and coworkers examined the eﬀect of ascorbate sup-
plementation on the incidence of postoperative AF in pa-
tientsundergoingCABGsurgery[15].Oralascorbicacidwas
given to 43 patients the night before and for 5 days after
CABG surgery. The incidence of POAF in the ascorbate sup-
plementation group was signiﬁcantly lower than in control
subjects (16.3% versus 34.9%, resp., P = 0.048). However,
it is worth noting that not all risk factors were adequately
matched between groups with a higher incidence of diabetes,
hypertension, and prior AF in the control group. On the
whole, these results support the hypothesis that antioxidant
treatment protects against electrophysiological remodeling
in AF and reduces incidence of postoperative AF.
The use of β-blocker therapy as standard prophylaxis
for the prevention of POAF in cardiac surgery is advocated
by evidence-based guidelines (NICE guidelines, American
College of Cardiology (ACC)/American Heart Association
(AHA)/European Society of Cardiology (ESC)) [52]. The
eﬃcacy of ascorbic acid as an adjunct to such β-blocker
therapy was evaluated in a prospective, randomised trial
[45]. One hundred patients over the age of 50 undergoing
CABG surgery were assigned to an ascorbic acid group or
control group. All patients received β-blockers for at least
a week prior to surgery and postoperatively. Patients in the
ascorbicacidgroupreceived2gascorbicacidthenightbefore
surgery and 1g ascorbic acid daily for 5 days postoperatively.
Patients in the control group received β-blocker therapy
alone. Incidence of POAF was 4% in the ascorbic acid group
and 26% in the control group (P = 0.002). In a simi-
lar randomised trial of 170 patients already receiving β-
blocker therapy, Papoulidis and colleagues studied the eﬀect
of ascorbic acid on patients undergoing ﬁrst-time isolated
CABG [12]. The incidence of POAF was signiﬁcantly lower
in the vitamin C group compared to the control (44.7%
versus 61.2%, resp., P = 0.041). The vitamin C group also
had signiﬁcantly lower intensive care unit stay. Additionally,
patients in the vitamin C group who did develop AF had
signiﬁcantly shorter time interval for conversion into sinus
rhythm. Vitamin C treatment, therefore, not only has been
shown to prevent AF when used alone, but also has synergis-
tic actions when used in combination with standard anti-AF
drug treatment [19].
Castillo and colleagues [47] investigated whether antiox-
idant therapy protocol with combined omega-3 polyunsat-
urated fatty acids (n-3 PUFAs) and antioxidant vitamins
reduces oxidative and inﬂammatory damage in cardiac tis-
sue. In this study, 95 patients received supplementation with
n-3 PUFA or placebo 7 days before on-pump surgery and
antioxidant vitamins C and E or placebo from day 2 before
surgery until hospital discharge. Atrial tissue was obtained
from patients during intervention. Oxidative stress damage
in atrial tissue was assessed by measuring the content of4 Cardiology Research and Practice
Table 1: Summary of experimental evidence for antioxidant vitamins in AF prevention.
Study Model Setting Intervention/groups Results Relevance to AF
Carnes et al.
2001 [15]
Instrumented
dogs—atrial
electrodes
External ATP Ascorbic acid versus control Attenuated
shortening of ERP Prevention
Shiroshita
Takeshita et al.
2004 [28]
Dogs—atrial
electrodes External ATP
control versus simvastatin
versus vitamin C versus
vitamin C & E
Vitamin C/E had no
eﬀect No eﬀect
Lin YK et al.
2010 [41]
Isolated rabbit PVs
and LA tissues
In vitro hydrogen peroxide
oxidation treatment Ascorbic acid versus control
Reduced PV
spontaneous activity
and abolished burst
PV ﬁring
Prevention
ATP: atrial tachypacing; ERP: eﬀective refractory period; LA: left atrium; PV: pulmonary vein.
Table 2: Summary of clinical evidence for the use of antioxidant vitamins in AF prevention.
Study Design N Setting Groups Endpoint Follow up Risk reduction
Sisto et al.
1995 [42] RCT 81 CABG
Vitamin C/vitamin
E/allopurinol
versus placebo
Arrhythmias
(including AF)
5d a y s
postoperative
30% absolute
risk reduction
(P = 0.05)
Carnes et al.
2001 [15]
Double-blinded,
placebo
controlled RCT
86 CABG Ascorbic acid
versus control AF detection 5d a y s
postoperative
18.6% absolute
risk reduction
(P = 0.048).
Lassnigg et al.
2003 [43]
Double-blinded
RCT 40 CABG/valve
surgery
all-rac-α-
tocopherol versus
placebo
Arrhythmias
(including AF)
6d a y s
postoperative
No eﬀect of
vitamin E on AF
Korantzopoulos
et al. 2005 [44]
Double-blinded
RCT 44 DCCV for
persistent AF
Vitamin C versus
placebo AF recurrence
1w e e kp o s t
successful
DCCV
conversion
31.8% absolute
risk reduction
(P = 0.024)
Eslami et al.
2007 [45] RCT 100 CABG
β-blockers +
ascorbic acid
versus β-blockers
alone
AF detection 4d a y s
postoperative
22% relative risk
reduction
(P = 0.002)
Hicks et al.
2007 [46]
Double-blinded
RCT 32 MI—for
thrombolysis
Antioxidant
vitamins (A, C, B
complex, vitamin
E) versus placebo
New-onset AF 2h o u r sp o s t
thrombolysis
38% absolute
risk reduction
(P<0.05)
Papoulidis et al.
2010 [12] RCT 170 CABG Vitamin C versus
placebo
AF and rhythm
restoration from
AF
5d a y s
postoperative
16.5% absolute
risk reduction
(P = 0.04)
Reduced ICU
stay (P = 0.05),
reduced
hospitalisation
time (P = 0.04)
and reduced
time needed for
conversion into
SR (P = 0.047)
Castillo et al.
2010 [47]
Double-blinded
RCT 95 CABG
n-3 PUFA/Vitamin
C and E versus
placebo
AF detection Hospital
discharge
9% absolute risk
reduction
(P = 0.32)
AF: atrial ﬁbrillation; RCT: randomised controlled trial; CABG: coronary artery bypass graft; DCCV: direct current cardioversion; MI: myocardial infarction;
ICU: intensive care unit; SR: sinus rhythm; n-3 PUFA: omega 3 polyunsaturated fatty acids.Cardiology Research and Practice 5
reducedglutathione(GSH)andoxidisedglutathione(GSSG)
ratio (GSH/GSSG), malondialdehyde (MDA) (a marker of
lipid peroxidation), and protein carbonylation. Atrial tissue
GSH/GSSGratiowas38.1%higherinsupplementedpatients
compared with placebo (P<0.01). There were also 27.5%
lower MDA levels and 24% lower protein carbonylation in
the supplemented group compared with placebo (P<0.01).
Patients who received PUFA-antioxidant supplementation
also showed lower levels of inﬂammatory biomarkers such as
leucocyte count and serum high sensitive CRP. In addition
atrial tissue activation levels of NF-kB, a transcriptional
messenger central to oxidative stress response, were lower
in patients supplemented with antioxidant therapy. NF-kB is
a response element of both oxidative stress and inﬂamma-
tory pathway which is involved in transcription and DNA
activation. The evidence from this study supports oxidative
and inﬂammatory-induced damage of cardiac myocytes in
ischaemia reperfusion event. Nonetheless, although there
wasatrendforlowerincidenceofPOAFinthesupplemented
patient group (22.9% versus 31.9%), this was not statistically
signiﬁcant (P = 0.325).
8.VitaminsandAF following ST-Elevation
MyocardialInfarction(STEMI)
In STEMI, restoration of blood ﬂow has been associated
with the release of ROS and reactive nitrogen species by
ischaemic tissues, endothelium, and leukocytes. This results
in cellular injury and may cause arrhythmia including AF,
temporary impairment of systolic function, and endothelial
dysfunction. The role of antioxidant vitamins in ischaemic
reperfusion injury after therapeutic thrombolysis in patients
who had a STEMI was examined by Hicks et al. [46]. Thirty-
two patients were randomly assigned to receive adjuvant
antioxidant vitamin supplements (vitamin A, vitamin B12,
thiamine, vitamin C, vitamin E, cofactors, and minerals),
while control group patients were given a placebo. Treatment
was administered after the diagnosis of STEMI was estab-
lished and then at 1, 4, and 12 hours after thrombolytic
therapy. The incidence of AF was signiﬁcantly reduced in
patients who received antioxidant vitamins compared to
controls (6% versus 44%, P<0.05). The incidence of other
arrhythmiassuchasventricularprematurebeatsandventric-
ular tachycardia was also signiﬁcantly less in the antioxidant
group. Furthermore, the neutrophil and total leukocyte
count signiﬁcantly decreased and plasma antioxidant capac-
ity signiﬁcantly increased 24 hours after reperfusion in
patientswhoreceivedantioxidanttherapy.Itisnotable,how-
ever, that 50% of patients in the multi-antioxidant-treated
group developed asymptomatic sinus bradycardia, although
thisdidnotrequiretreatmentorhaveanyidentiﬁableimpact
on morbidity or mortality. In addition, the simultaneous ad-
ministration of a combination of vitamins and minerals
makes it diﬃcult to ascribe the observed beneﬁt to a single
agent. The decrease in AF is postulated to be the result of
an increase in plasma antioxidant capacity and consequent
neutralisation of ROS by antioxidant vitamins.
9.Secondary Preventionof AF withVitaminC
The concept of utilising non-antiarrhythmic medications
for the prevention of AF recurrence following electrical
cardioversion, chemical cardioversion, and AF ablation has
recently become topical following some encouraging results
with statins, angiotensin-converting enzyme inhibitors, and
angiotensin receptor blockers [50]. Korantzopoulos et al.
examined the eﬀect of oral vitamin C on early recurrence
rate of AF after electrical cardioversion of persistent AF
[44]. Oral vitamin C was given 12 hours before and for 7
days after cardioversion. AF recurred in 4.5% of patients
who received vitamin C supplements compared to 36.3% of
patients in the control group (P = 0.024). Given that early
recurrence of AF following cardioversion is thought to be the
result of atrial electrical remodeling [14, 53], this supports
the role of vitamin C in protecting against recurrence of
AF by attenuating this process [44]. In addition, this study
demonstratedthatseruminﬂammatoryindices,suchasCRP,
ﬁbrinogen, and white blood cell count were also signiﬁcantly
reduced in patients supplemented with vitamin C.
10. Vitamin E in AF Prevention
In a study by Sisto and colleagues, 37 patients undergoing
CABG surgery received oral vitamin E for 28 days prior to
elective surgery or for 2 days prior to urgent surgery for
patients presenting with unstable disease [42]. Both patient
groups also received vitamin C and allopurinol for two days
prior to surgery and for one day after surgery. A further
44 patients were recruited as controls. Although vitamin
E supplementation failed to maintain postoperative plasma
vitamin E levels in the unstable patients, this group had
reduced incidence of arrhythmias (12% versus 42%, P =
0.05). Furthermore, relative to the control group, both treat-
ment groups had signiﬁcantly fewer electrocardiographic
ischaemic events and lower incidence of perioperative MI.
An important limitation is that the incidence of arrhythmias
in this study was reported collectively, making it diﬃcult
to get an accurate representation of incidence of AF alone.
Additionally, due to the use of combination therapy (vitamin
C, vitamin E, and allopurinol), it is diﬃcult to ascribe the
favourable outcome to a single agent.
A study by Lassnigg et al. assessed the eﬀect of vitamin
E infusions in patients undergoing CABG or valve surgery
given for 12–16 hours before and for 48 hours postopera-
tively [43]. As plasma ROS is diﬃcult to measure directly,
malondialdehyde levels (a secondary reactive product) and
plasma depletion of vitamin C and E were measured as an
indication of oxidative stress. Although vitamin E supple-
mentation maintained plasma vitamin E concentrations, it
did not have an eﬀect on the increase in malondialdehyde or
thedecreaseinplasmaantioxidant status,whichwasassessed
by measuring plasma bilirubin and uric acid levels. In
addition, infusion of vitamin E did not prevent the decrease
in plasma vitamin C concentration. The authors question
the ability of vitamin E supplementation, without adjuvant
vitamin C, in blocking the formation of ROS. This is in
accordwiththeearliermentionedobservationthatvitaminE6 Cardiology Research and Practice
requires electron donation by vitamin C for regeneration of
its antioxidant capacity after a single interaction with a ROS.
11. Other AntioxidantsinAFPrevention
In addition to antioxidant vitamins, some other antioxidant
interventions such as N-acetylcysteine (NAC) [54] and nitric
oxide [55] have shown promising clinical beneﬁts in reduc-
ing oxidative stress and postoperative AF. NAC, a glutathione
precursor, is an antioxidant agent that reduces cellular
oxidative damage. NAC has been shown to increase L-type
calcium channel current and reverse AF-induced remodeling
of ion channels [56]. The eﬀect of NAC in the prevention of
POAF was evaluated in a prospective, double-blind placebo-
controlled trial of 115 patients undergoing CABG and/or
valve surgery [54]. The incidence of POAF was lower in
the NAC group (5.2%) compared with the placebo group
(21.1%) (P = 0.019). Nitric oxide, an indirect antioxidant,
has also shown to be beneﬁcial in reducing incidence of
POAF. Cavolli et al. [55] evaluated the eﬀect of sodium
nitroprusside (SNP), a nitric oxide donor, in the prevention
ofPOAFin100patientsundergoingCABG,withnoprevious
history of AF. The incidence of POAF was 12% in the
SNP group and 27% in the control group (P<0.005).
In addition, patients treated with SNP showed signiﬁcantly
shorter duration of POAF (5.33 ± 1.86 and 7.55 ± 1.94 h,
resp.; P = 0.023). Other more potent antioxidants also merit
consideration such as astaxanthin, the prototype oxygenated
carotenoid or the membrane-permeable scavenger tempol
[57]. The eﬀectiveness of these agents remains to be evalu-
ated in further larger studies.
12.Challenges andPerspectivesofAntioxidant
Agents in AF Prevention
Clinical and experimental studies in the antioxidant and,
possibly, the antiarrhythmic role of vitamins have provided
some useful insights. However, a paradigm shift in this
approach to AF prevention may be in store. Using vitamins
or other antioxidants to neutralise the already formed in-
tracellular ROS may be trying to lock the door after the
horse has bolted. Therapy may, in fact, be better targeted
at preventing ROS formation. Studies into the mechanisms
of myocardial ROS formation are paving the way for this
therapeutic approach. A study by Kim et al. focused on the
source of superoxide generation in atrial appendages excised
during cardiac surgery from patients with AF compared to
control. They found increased activity of NADPH oxidase-
2 in AF patients and signiﬁcant superoxide production by
nitric oxide synthases (NOS), suggesting “uncoupling” of
this enzyme in AF leading to mitochondrial ROS forma-
tion [27]. Although this “uncoupling” may, itself, be a
consequence of prior initiating oxidative stress, it provides
a novel therapy target. Kim et al. demonstrated reduced
b a s a ll e v e l so fs u p e r o x i d ei nt h eh o m o g e n a t e so fa t r i a
from AF patients treated with the mitochondrial inhibitor
rotenone. Tetrahydrobiopterin (BH4), a NOS cofactor, can
help“recouple”NOSandpreventROSformation.Inarecent
abstract of their work, Nishijima et al. report that BH4
reduced inducibility of atrial ﬁbrillation and increased atrial
ERP in a tachypacing canine model of heart failure, raising
hopes for the “NOS recoupling” approach to AF prevention
[58].
13. Conclusions
Increasing evidence links oxidative stress with the pathogen-
esis of electrophysiological and structural remodeling pro-
cesses that perpetuate AF. Most current available therapies
exhibit limited eﬃcacy, are associated with considerable side
eﬀects, and may confer no prognostic beneﬁt. Evidence from
clinical and experimental studies into the use of antioxidant
vitamins in AF prevention indicates that antioxidant vita-
mins have role in risk reduction of AF. The eﬀect, however,
is somewhat variable. An explanation as to why we are not
seeing a stronger eﬀect may be because both vitamin C and E
areweakantioxidants,andvitaminE,unlikestrongerantiox-
idants(e.g.,tempol),requireselectrondonationafterasingle
interaction with a ROS. Furthermore, at usual oral doses,
these vitamins have limited capacity to cross the cell mem-
brane and get to where the superoxide is being produced.
Future studies should possibly include the assessment of
stronger antioxidant agents, such as tempol, and strive to
improve assays of in vivo oxidative stress status. In addition,
the exact mechanism by which oxidative stress leads to
atrial remodeling and AF needs to be elucidated further
whereas larger-scale clinical studies are required to conﬁrm
the beneﬁts of antioxidant vitamins before they can be
considered for routine use.
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